Orforglipron (Foundayo): Weight Loss Results and Cost
Orforglipron is a daily GLP-1 pill sold as Foundayo, and it is built differently from every GLP-1 medicine before it. This page explains what it is, its approval status, what the weight loss trials found in plain words, and what the manufacturer says it costs.
What orforglipron is
Orforglipron is a GLP-1 receptor agonist, so it works on the same hormone pathway as semaglutide and tirzepatide: appetite falls, food moves through the stomach more slowly, and blood sugar handling improves. The difference is in the chemistry. Semaglutide and tirzepatide are peptides, large fragile molecules copied from natural hormones. Orforglipron is a small molecule, a compact man made compound designed to switch on the same GLP-1 receptor. It is made by Eli Lilly and sold under the brand name Foundayo, as a tablet taken once a day.
That small molecule design is the point of the product. Peptides are broken down in the stomach, which is why the older drugs are injections, and why the semaglutide tablet needs its strict empty stomach routine. A small molecule survives digestion far more easily, so orforglipron was designed from the start to be a straightforward daily pill.
Approval status
Foundayo is an FDA approved medicine. Eli Lilly announced that the FDA approved Foundayo (orforglipron) on April 1, 2026, and the product became available in the United States shortly after, through LillyDirect, telehealth providers and retail pharmacies. Its approved use is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight who also have at least one weight related medical condition, alongside a reduced calorie diet and increased physical activity.
It is a prescription medicine, not a supplement, and it is not the same as the injectable Lilly products Mounjaro and Zepbound, whose active ingredient is tirzepatide. Orforglipron also has its own label, with its own strengths, instructions and warnings, including the class boxed warning about thyroid C-cell tumors and the MEN 2 and medullary thyroid carcinoma contraindication that runs across this family of medicines.
A daily pill with no food or water restrictions
The practical headline from the manufacturer is convenience. Lilly describes Foundayo as the GLP-1 pill for weight loss that can be taken at any time of day, without food or water restrictions. That is a real contrast with oral semaglutide, where the tablet has to be taken first thing on an empty stomach with a small amount of water, followed by at least a 30 minute wait before eating, drinking or taking other medicines. For people whose mornings are crowded with other medication, breakfast or a commute, a pill that fits anywhere in the day removes a common point of failure.
Convenience is not the same as superiority, though. A pill that is easier to take still has to suit the person, their other conditions and their prescriber judgment, and the daily routine only helps if the medicine itself is the right choice.
Weight loss results, in plain words
In the main weight loss trial programme, called ATTAIN, people taking orforglipron lost substantially more weight than people taking a placebo over a treatment period of a little over a year. Lilly reported that, at the highest dose, the average loss was in the high twenties of pounds. People on lower doses lost less on average, and as with every medicine in this class, individual results varied widely around the averages.
Two honest limits belong next to those results. First, trial averages are not promises: they describe groups of people in a supervised study, not what any one person will lose. Second, there is no head to head trial behind this page to rank Foundayo against the injectable medicines or the Wegovy pill, and results from separate trials with different designs should not be treated as a direct contest. The fair summary is that the trials showed meaningful, clearly more than placebo weight loss from a once daily pill, which is why the approval drew so much attention.
Side effects in words
The effects listed for Foundayo are the familiar GLP-1 pattern. The label lists nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, tiredness, belching, heartburn and hair loss among its common effects. As with the rest of the class, stomach effects tend to be most noticeable while the dose is being increased, and the label advises that using it together with another GLP-1 receptor agonist is not recommended. Anyone with severe or persistent symptoms should contact their care team promptly rather than simply stopping or pushing through on their own.
Foundayo cost: what the manufacturer reports
For the foundayo cost question, the clearest figures are the ones Lilly itself published at launch, so they are stated here exactly as manufacturer reported prices. Lilly said Foundayo starts at $149 per month at the lowest dose for self pay patients buying through LillyDirect. Eligible people with commercial insurance coverage for Foundayo may pay as little as $25 per month with the Foundayo savings card. Lilly also said eligible Medicare Part D patients may be able to get Foundayo for $50 per month, beginning July 1, 2026.
These are launch figures from the manufacturer, not a promise of what any one person will pay. Higher doses were priced above the starting dose in Lilly reporting, the final amount depends on your dose, your insurance coverage and where the prescription is filled, and prices and programmes can change after launch. The pharmacy or LillyDirect can confirm a current price for a specific prescription before you commit to it.
Frequently asked questions
Is orforglipron FDA approved?
Yes. Eli Lilly announced FDA approval of Foundayo (orforglipron) on April 1, 2026, for reducing excess body weight and maintaining weight reduction long term in adults with obesity, or overweight with at least one weight related condition, alongside a reduced calorie diet and increased physical activity. It is a prescription medicine.
How is orforglipron different from semaglutide?
Orforglipron is a small molecule that activates the GLP-1 receptor, while semaglutide is a peptide copied from a natural hormone. Both work on the same pathway, but the small molecule survives digestion easily, so orforglipron is a once daily pill with no food or water restrictions, instead of a weekly injection or a tablet with a strict fasting routine.
Do you have to fast before taking Foundayo?
No. The manufacturer describes Foundayo as a pill that can be taken at any time of day, without food or water restrictions. That is a key difference from oral semaglutide tablets such as Rybelsus and the Wegovy pill, which must be taken on an empty stomach with a 30 minute wait afterwards.
How much weight did people lose on orforglipron in trials?
In the ATTAIN trial programme, people taking orforglipron lost substantially more weight than people on placebo over a little over a year of treatment. Lilly reported an average loss in the high twenties of pounds at the highest dose. Averages describe trial groups, not a guarantee for any individual, and lower doses produced smaller average losses.
What does Foundayo cost?
As reported by Lilly at launch, self pay pricing through LillyDirect starts at $149 per month at the lowest dose. Eligible commercially insured patients may pay as little as $25 per month with the Foundayo savings card, and eligible Medicare Part D patients may pay $50 per month from July 1, 2026. Your actual cost depends on dose, coverage and pharmacy.